InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Monday, 06/03/2019 8:00:41 AM

Monday, June 03, 2019 8:00:41 AM

Post# of 932
News: $GNCA Genocea's GEN-009 Vaccine Demonstrates Best-in-Class Immune Responses to ATLAS(TM)-selected Neoantigens in Cancer Patients

    Post-vaccination T cell responses detected to 91% of vaccine neoantigens, including CD8 + T cell responses to 53% of vaccine neoantigens Conference call and webcast to discuss results TODAY at 8:30 am ET CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) --...

Read the whole news https://marketwirenews.com/news-releases/genocea-s-gen-009-vaccine-demonstrates-best-in-class-immune-responses-to-atlas-tm-selected-neoantigens-in-cancer-patients-8287592.html